WallStreetZenWallStreetZen

NASDAQ: KRYS
Krystal Biotech Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Krystal Biotech earnings were $241.5M for the trailing 12 months ending Jun 30, 2026, with 61.8% growth year over year. The latest KRYS earnings report on Jun 30, 2026 announced Q2 2026 earnings of $54.8M, down 2.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, KRYS reported annual earnings of $204.8M, with 129.7% growth. The next KRYS earnings date is Nov 2, 2026.

KRYS past earnings growth

How has KRYS's earnings growth performed historically?

Company
61.84%
Industry
18.1%
Market
92.82%
KRYS's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
KRYS's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
KRYS's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

KRYS earnings history

Current Revenue
$440.5M
Current Earnings
$241.5M
Current Profit Margin
54.8%

KRYS Return on Equity

Current Company
19.3%
Current Industry
-13.6%
Current Market
30.9%
KRYS's Return on Equity (19.3%)... subscribe to Premium to read more.
High Return on Equity Performance

KRYS Return on Assets

Current Company
17.7%
Current Industry
-10.2%
KRYS is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when KRYS announces earnings.

KRYS Return on Capital Employed

Current Company
16.5%
Current Industry
-6.7%
KRYS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

KRYS vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
KRYS$233.29M$241.47M+48.11%$8.27
KYMR-$291.04M-$299.60MN/A-$3.25
CYTK-$826.65M-$894.00MN/A-$7.22
ARWR-$181.49M-$319.95MN/A-$2.25
PTGX$87.21M$82.91M-34.84%$1.21
View Top Biotech Stocks

KRYS earnings dates

Next earnings date
Nov 2, 2026

Krystal Biotech Earnings Reports & History FAQ

What were Krystal Biotech's earnings last quarter?

On KRYS's earnings call on Aug 3, 2026, Krystal Biotech (NASDAQ: KRYS) reported Q2 2026 earnings per share (EPS) of $1.85, up 39.1% year over year. Total KRYS earnings for the quarter were $54.77 million. In the same quarter last year, Krystal Biotech's earnings per share (EPS) was $1.33.

If you're new to stock investing, here's how to buy Krystal Biotech stock.

When does Krystal Biotech report earnings?

The next KRYS earnings call is Nov 2, 2026. Add KRYS to your watchlist to be reminded of Krystal Biotech's next earnings date.

Is Krystal Biotech profitable or losing money?

As of the last Krystal Biotech earnings report, Krystal Biotech is currently profitable. Krystal Biotech's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $241.47 million, a 64.57% increase year over year.

What was KRYS's earnings growth in the past year?

As of Krystal Biotech's earnings date in Aug 3, 2026, Krystal Biotech's earnings has grown 61.84% year over year. This is 43.74 percentage points higher than the US Biotechnology industry earnings growth rate of 18.1%. KRYS earnings in the past year totalled $241.47 million.

What are Krystal Biotech's earnings expectations?

The current EPS estimate for Krystal Biotech's earnings report in Nov 2, 2026 is $1.91.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.